This experimental COVID-19 vaccine is developed by Moderna Therapeutics, a US biotech firm, has generated a positive response in a second human trial.
A total number of 45 healthy persons has been tried with the vaccine.
The result of the trial was published in a journal on Tuesday.
The 45 persons were within the age of 18-45. They were vaccinated at the hospital in Washington.
All of the volunteers were injected with the vaccine since about a month ago.
The results shows that the volunteers developed antibodies to the virus.
The study said when the antibodies were tested against a lab version of SARS-CoV-2, the antibodies neutralised the virus as effectively as antibodies taken from people who were naturally infected with SARS-CoV-2 and recovered.
On the safety of the vaccine, the study said no major side effect was recorded as participants only experienced minor fatigue, chills, headache, myalgia, and pain at the injection site.
“No serious adverse events were noted, and no pre-specified trial halting rules were met,” the study read.
“Local adverse events, when present, were nearly all mild or moderate, and pain at the injection site was common. Across both vaccinations, solicited systemic and local adverse events that occurred in more than half the participants included fatigue, chills, headache, myalgia, and pain at the injection site.”
Although, it is not clear how long the vaccine can prevent the virus, the study said the 45 participants will be monitored for a long time.
Reacting to the development, Lisa Jackson, the study’s lead author, said the results indicated progress in the quest for an effective vaccine against COVID-19.
“We saw robust responses after the second vaccination. It seems that two doses are needed, which is what is expected from this type of vaccine and from a vaccine against an emerging virus that hasn’t been present in the population. The immune system needs to be set up by the first dose to then respond more vigorously to the second one,” she said.
The US Food and Drug Administration has authorised that next phase of the study involving 30,000 people.
The study will also compare the efficacy of the vaccine against a placebo.
Moderna was announced as one of the five vaccine developers chosen to be part of US President Donald Trump’s operation warp speed program to accelerate development of a COVID-19 vaccine.
There has been pressure to develop a vaccine against COVID-19 which has disrupted routine activities across the world.
Gilead Sciences, a biopharmaceutical company in the US, is also at the forefront of finding a vaccine for the disease.